Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations

Study Overview
=================
Brief Summary
-----------------
This clinical trial is to verify the safety and effectiveness of the Non-adhesive Liquid Embolic System(NALES) produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. in the process of clinical use to support the application of the National Medical Products Administration ( NMPA) product registration approval.

Detailed Description
-----------------
A prospective, multicenter, randomized controlled trial was used in this study. Onyx Liquid Embolic System and Marathon Flow Directed Micro Catheter, which were registered and marketed in China and had good effect in the industry, were selected as the control devices. Subjects requiring cerebral arteriovenous malformation embolization were selected to participate in the trial based on pathological conditions and inclusion/exclusion criteria, and the use of test products or control products was determined based on central randomized results. Imaging data involving the main evaluation criteria were evaluated uniformly by the blind evaluators of the leading unit, so as to reduce the bias caused by subjective factors of different evaluators.

Official Title
-----------------
A Prospective, Multi-center, Randomized Parallel Controlled Study on the Safety and Effectiveness of the Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations

Conditions
-----------------
Intracranial Arteriovenous Malformations

Intervention / Treatment
-----------------
* Device: embolism


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-70 years old, no gender limit. The patient was diagnosed as cerebral arteriovenous malformation . The patient had no history of bAVM treatment, including intervention, surgery or radiotherapy . Spetzler Martin, grade I-IV . The patient voluntarily signed the informed consent. Exclusion Criteria: History of heparin allergy. The patient is allergic to contrast media. Severe hepatic and renal insufficiency (serum creatinine ≥1.5 times the upper limit of normal value, alanine aminotransferase ≥3 times the upper limit of normal value, aspartate aminotransferase ≥3 times the upper limit of normal value). Patient has irreversible coagulopathy (INR > 1.5). Intracranial hemorrhage 1 week before treatment. MRS ≥4 due to neurological dysfunction. Patients with planned malformation resection after embolization. Blood flow related aneurysms of supplying artery that need to be treated by other methods. Complicated with severe cerebral artery stenosis. Brain tumors that require recent surgery. Complicated with proliferative cerebrovascular disease. Pregnant or lactating women. Participants who have participated in other clinical trials within the last 3 months and failed to reach the end point. The number of embolism is expected to be greater than or equal to 4 times during the study period (within 1 year). Subjects deemed unsuitable for this study by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Non-adhesive Liquid Embolic System(NALES)<br> | Device: embolism<br>* Cerebral arteriovenous malformation embolism<br>|
| Active Comparator: Onyx Liquid Embolic System& Marathon Flow Directed Micro Catheter<br> | Device: embolism<br>* Cerebral arteriovenous malformation embolism<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective embolization rate of malformed masses | Number of effective embolization subjects / Total number of subjects x 100%.Definition of effective embolization : Postoperative DSA angiographic malformation volume decreased ≥50%. Volume of malformed groups = length × width × height /2. | Immediately after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRS score | MRS refers to the modified Rankin scale, which is used to measure the neurological recovery of patients after stroke. It has a scale of zero to six. The higher the score, the worse the neurological function. MRS scores were collected at 1, 6 and 12 months after the operation before discharge . | 1,6,12months after surgery | 
| Technical success rate | Success is represented by the ability to reach the lesion and embolize the malformed mass of the intended target, followed by successful catheter withdrawal from the body | Immediately after surgery | 
| Catheter performance evaluation | The ability of the catheter to reach the lesion . The catheter has broken at the tip and perforated. Intravascular complications associated with catheters occurred. Degree of difficulty in tube withdrawal Catheter jam | Immediately after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-adhesive Liquid Embolic System